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ABSTRACT 
Objective: To develop and validate a simple, precise, and rapid liquid chromatographic-tandem mass spectrometric (LC-MS/MS) method for 
quantification of amlodipine in human plasma.  
Methods: Chromatographic analysis was performed on Atlantis dC18 column (2.1 x 100 mm, 3 µm) with a mobile phase consisting of acetonitrile 
and 10 mM formic acid (80:20, v: v) that was delivered at a flow rate of 0.3 ml/min. The eluents were monitored using electrospray ionization in the 
positive ion mode set at transition 409 → 238.4 and 254.3 → 43.9 for amlodipine and tizanidine hydrochloride (IS), respectively. The method was 
validated for linearity, accuracy, precision, and recovery as per US-FDA guidelines.  
Results: The retention times of amlodipine and tizanidine (IS) were 1.26 and 1.22 respectively. The relationship between amlodipine concentration 
and peak height ratio of amlodipine to the IS was linear (R2
Conclusion: The proposed method is simple, precise, and accurate for rapid measurement of amlodipine level using 0.5 ml human plasma. Further, 
the assay was successfully applied to determine amlodipine level in human plasma samples obtained from a healthy volunteer.  
≥ 0.9868) in the range of 0.2–20 ng/ml, and the intra-and inter-day coefficient of 
variations and bias were ≤14.4% and ≤13.6% and ≤13.7% and ≤11.2%, respectively.  
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INTRODUCTION 
Amlodipine (CAS: 88150-42-9), a derivative of dihydropyridine, is 
widely used in the treatment of hypertension. It lowers blood 
pressure by inhibiting the influx of calcium ions 
Various analytical methods have been reported for quantification of 
amlodipine in human plasma. They include thin-layer chromate-
graphy (TLC) [4], gas chromatography equipped with electron capture 
detection (GC-ECD) [5, 6], high-performance thin-layer chroma-
tography (HP-TLC) [7], high performance liquid chromate-graphy 
(HPLC) with ultra-violet (UV) detection [8, 9], fluorimeteric detection 
[10, 11]or electrochemical detection [12], and liquid chromatography-
tandem mass spectrometry (LCMS-MS) [13-15]. In general, HPLC with 
UV detection is the preferred method for quantification of analytes 
that have strong absorbance in the UV range. Because amlodipine has 
low absorbance in UV range, most reported assays used either pre-
column derivatization with 4-chloro-7-nitrobenzofurazan or 
LCMS/MS. There is limited data on the stability of amlodipine in 
processed and unprocessed human plasma
[1]. Its absolute 
bioavailability is in the range of 60-65%, and it has a peak plasma 
concentration of 6-12 ng/ml within 8-10 h after the ingestion of a 10 
mg therapeutic dosage [2, 3].  
The present manuscript describes a precise and rapid LCMS/MS 
assay for quantitative determination of amlodipine in human plasma 
using tizanidine as an internal standard. The method involves simple 
liquid/liquid extraction, using 500 µl human plasma. The validated 
method was used to determine the stability of amlodipine under 
various clinical laboratory conditions, particularly in unprocessed 
human plasma samples for more than one year and has been 
successfully used to determine amlodipine level in human plasma 
samples obtained from a healthy volunteer.  
 [9, 14].  
MATERIALS AND METHODS 
Chemicals and reagents 
All chemicals were of analytical grade unless stated otherwise. 
Amlodipine USP reference standard and tizanidine hydrochloride 
(IS) were purchased from Sigma-Aldrich Co., St. Louis, MO, USA. 
Acetonitrile, methanol, dichloromethane, formic acid and tert. butyl 
methyl ether (HPLC grade) were purchased from Fisher Scientific, NJ. 
USA. Water for HPLC was prepared by reverse osmosis and further 
purified by using synergy water purification system (Millipore, 
Bedford, MA, USA). Drug-free human plasma was obtained from the 
blood bank of King Faisal Specialist Hospital and Research Centre 
(KFSHRC) Riyadh, Saudi Arabia. The study was approved by the 
Research Ethics Committee of KFSHRC, under Research Advisory 
Council (RAC# 2101100).  
Instrument and chromatographic conditions 
LC-MS/MS analysis was performed on Waters Alliance HPLC 2695 
Separation module, consisting of quaternary pump, autosampler, 
column thermostat, and Micromass Quattro micro API bench-top 
triple quadruple mass spectrometer, interfaced with Z-spray electro-
spray ionization probe. Data acquisition and analysis were 
performed using MassLynx 4.0 software with Quan Lynx program 
(Waters Associates Inc, Milford, MA, USA).  
Analysis was performed on a reversed phase Atlantis dC18 (2.1 X 
100 mm, 3 µm) column equipped with Symmetry C 18 (3.9 x 20 mm, 
5 µm) guard column. The mobile phase, composed of acetonitrile 
and 10 mM formic acid (80:20, v: v), was filtered through a 0.22 µm 
membrane filter (Millipore Corporation, Bedford, MA, USA), 
degassed, and delivered at a flow rate of 0.3 ml/min. MassLynx 
software working under Microsoft Window XP professional 
environment was used to control the instruments, data acquisition, 
peak integration, peak smoothing, and signal-to-noise ratio 
measurements. The electrospray ionization source was operated in 
the positive-ion mode at a capillary voltage of 4.0 kV and a cone 
voltage of 10 V. Nitrogen was used as nebulizing and desolvation gas 
at a flow rate of 60 and 600 L/hr, respectively. Argon was used as 
the collision gas at a pressure of 1.28 x 10-3 mbar. The optimum 
collision energy for amlodipine and tizanidine hydrochloride 
(internal standard, IS) was 25 eV. The ion source and the desolvation 
temperatures were maintained at 105 and 350  ̊C, respectively. The 
product ion transitions response were recorded at m/z 409.8 → 
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238.4 for amlodipine and 254.3 → 43.9 for the IS.  The assay was 
used to measure amlodipine stability in processed and unprocessed 
samples. 
Preparation of standard and control samples 
Amlodipine and the IS stock solutions were prepared in methanol 
(1.0 µg/ml). Calibration standards at nine different concentrations 
(0.2-20 ng/ml) and quality controls at four concentrations: (0.2, 0.6, 
10, and 18 ng/ml) were prepared in human plasma. IS working 
solution was prepared in methanol (30 ng/ml). Standard and control 
solutions were vortexed for one minute, and 500 µl aliquots were 
transferred into 7 ml glass culture tubes and stored at-20°C until 
used. 
Preparation of samples 
100 µl of the IS working solution was added to each 500 µl plasma 
sample, calibration standard, or quality control samples in a 7 ml 
glass culture tubes and vortexed for 30 seconds. 4.0 ml extraction 
solvent mixture of tert. butyl methyl ether and dichloromethane 
(7:3,v: v) was added to each tube, vortexed for one minute, and 
centrifuged at 6000 rpm for 10 min at room temperature. The clear 
supernatant layer was transferred to a clean borosilicate culture 
tube and dried under gentle steam of nitrogen at 40°C. The residue 
was reconstituted in 100 µl mixture of methanol and water mixture 
(1:1, v; v), and 10 µl of the clear solution was injected into the LC-
MS/MS system.  
Stability studies  
Two QC samples (0.6 and 18 ng/ml) were used for stability studies. 
Five aliquots of each sample were extracted and immediately 
analyzed (baseline). Five aliquots were allowed to stand on the 
bench-top for 24 h at room temperature before being processed and 
analyzed, five aliquots were stored at-20  ̊C for 68 w before being 
processed and analysis, and five aliquots were processed and stored 
at room temperature for 24 h or at-20  ̊C for 48 h before analysis. 
Fifteen aliquots were stored at −20 °C for 24 h. They were then left 
to completely thaw unassisted at room temperature. Five aliquots of 
each sample were analyzed and the rest stored at to-20  ̊C for 
another 24 h. The cycle was repeated three times. 
RESULTS AND DISCUSSION  
Optimization of LC and MS/MS conditions 
Fig. 1 depicts the chemical structure of amlodipine and tizanidine, 
the internal standard (IS) used in the study. The mass spectrometric 
conditions were optimized by infusing a standard solution of the 
amlodipine and the IS with a syringe pump. Precursor and product 
spectra of amlodipine and IS are shown in fig. 2. The product ion 
transitions response were quantitatively measured as peak height at 
m/z 409.8 → 238.4 for amlodipine and 254.3 → 43.9 for the IS . The 
chromatographic conditions were optimized using mobile phase 
composed of 10 mM formic acid and acetonitrile (20:80, v: v) at flow 
rate 0.3 ml/min. Data were recorded in multiple reaction monitoring 
(MRM) mode.  
 
 
Fig. 1: Chemical structures of amlodipine and tizanidine (IS) 
 
 
Fig. 2: Product ion spectrum of amlodipine and tizanidine (IS) 
 
Effect of matrix  
Generally, electrospray ionization is the most applicable method for 
bioanalysis. However, it is much more susceptible to matrix effects 
compared to atmospheric chemical ionization [16]. In present study, 
matrix effect was evaluated by comparing the peak response 
obtained from spiked plasma samples after sample preparation with 
the peak response obtained from direct injection of corresponding 
concentrations of amlodipine. No significant difference in response 
was observed.  
Method validation  
The method was validated according to standard procedures 
described in the US Food and Drug Administration (FDA) 
bioanalytical method validation guidance [17]. The validation 
Kashefi et al. 
Int J Pharm Pharm Sci, Vol 8, Issue 8, 268-272 
 
270 
parameter included: specificity, recovery, linearity, accuracy, 
precision and stability. 
Specificity 
In order to evaluate specificity, we screened six batches of blank plasma 
and eight frequently used medications (aspirin, acetaminophen, ascorbic 
acid, ibuprofen, caffeine, nicotinic acid, omeprazole, and ranitidine) for 
potential interference. No interference was found by plasma 
components, and none of the drugs co-eluted with amlodipine or the IS. 
Fig. 3 depicts a representative chromatogram of drug free human plasma 
that was used in preparation of calibration curve and quality control 
samples. Fig. 4 depicts LCMS/MS chromatograms of plasma spiked with 




Fig. 3: MRM chromatogram of blank human plasma used in preparation of standard and quality control samples 
 
 
Fig. 4: MRM chromatograms of quality control plasma samples spiked with tizanidine (IS, 30 ng/ml) and amlodipine at three 
concentrations 0.6, 10.0 and 18 ng/ml 
Kashefi et al. 




Recovery of amlodipine was assessed by comparing analyses’ peak 
heights obtained from spiked plasma and mobile phase samples, 
using five replicates of four concentrations (0.2, 0.6, 10 and 18 
ng/ml) for amlodipine and 30 ng/ml for IS. Recoveries were in range 
of 62-79 % for amlodipine and 95 % for the IS. The results are 
presented in table 1. 
  
Table 1: Extraction recovery of amlodipine and tizanidine (IS) 
Amlodipine   Human plasma, *Mean (SD) Mobile phase, *Mean (SD) †Recovery (%) 
0.2 (ng/ml) 133 (17) 216 (40)  62 
0.6 (ng/ml) 390 (44) 573 (37)  68 
10 (ng/ml) 6857 (785) 8632 (506) 79 
18 (ng/ml) 9758 (990) 12873 (792) 76 
IS (30 ng/ml) 17874 (1283) 18896 (1154) 95 
*Mean peak height of 5 replicate. †Mean peak height of amlodipine in human plasma divided by mean peak height in mobile phase X 100. SD, 
standard deviation. 
 
Linearity and limit of quantification  
Linearity of the assay was evaluated by analyzing a series of 
standards at nine different concentrations over the range of 0.2–20 
ng/ml. Corresponding peak height ratios and concentrations were 
subjected to regression analysis. The mean equation obtained from 
ten standard curves was y= 0.0457-0.0022x, with r2
Accuracy and precision  
 (SD) = 0.9868 
(0.011). The detection and quantification limits were as 0.1 ng/ml 
and 0.2 ng/ml, respectively. 
Accuracy and precision were determined by measuring levels of 
amlodipine in four spiked human plasma samples (0.2, 0.6, 10 and 
18 ng/ml). The intra-and inter-day imprecision and bias were 
determined over three different days. Intra-day (n=10) 
imprecision and bias were ≤ 14.4% and±13.7%, respectively. 
Inter-day (n=20) imprecision and bias were ≤13.6% and ≤11.2%, 
respectively (table 2). 
 
Table 2: Intra-and inter-run precision and accuracy of amlodipine assay 
Nominal 
level (µg/ml) 
 Intra-day (n=10) measured level Inter-day (n=20) measured level 
 Mean (SD)  CV (%) Bias (%) Mean (SD) CV (%) Bias (%) 
0.2  0.22 (0.03)  14.2 9.8 0.21 (0.03) 12.7 5.3 
0.6  0.64 (0.09)  13.7 5.9 0.66 (0.08) 11.6 9.2 
10 10.54 (1.52) 14.4 5.4 10.07 (1.37) 13.6 0.7 
18 20.47 (2.14) 10.5  13.7 20.01 (2.35) 11.7 11.2 
SD, standard deviation. CV, coefficient of variation = standard deviation divided by mean measured concentration x 100. Bias = measured level-
nominal level divided by nominal level x 100. 
 
Stability 
It is necessary to perform stability studies of the analyte and IS to 
determine the range of appropriate conditions and times of storage. 
In pharmacokinetic and/or bioequivalence investigations, 
documentation of long-term stability of the analyte is a pre-
requisite. There may be a long elapsed time between start of 
sampling and end of analysis. The availability of stability studies for 
extended period is essential for study planning and results 
interpretation. Previous studies did not address stability of 
amlodipine in human plasma beyond three months.  
In the present study, amlodipine and IS stability in processed and 
unprocessed plasma samples was investigated. Amlodipine in 
processed samples (0.6 and 18 ng/ml) was found to be stable for 24 
h at room temperature (≥ 93%) and 48 h at-20  ̊C (≥ 92%); in 
unprocessed plasma samples was stable for at least 24 h at room 
temperature (≥93%), sixty eight weeks at-20  ̊C or below (≥91 %), 
and after three freeze-and thaw cycles (≥88%). The data are 
summarized in table 3. Further, no significant change in 
chromatographic behavior of amlodipine or the IS was observed 
under any of the above conditions. 
 
Table 3: Stability of amlodipine in different conditions 
Storage condition Nominal level ng/ml Measured level mean±SD ng/ml  Stability (%) 
Baseline (0h) 0.6 0.60 (0.05)  
 18 18.09 (1.21)  
Processed samples    
24 h (RT) 0.6 0.57 (0.16) 95 
 18 16.87 (2.35)  93 
48 h (-20  ̊C) 0.6 0.55 (0.09) 92 
 18 18.44 (2.71) 102 
Unprocessed samples    
24 h (RT) 0.6 0.56 (0.04) 93 
 18 18.44 (1.17) 102 
68 w (-20  ̊C) 0.6 0.55 (0.02) 91 
 18 16.93 (1.40) 93 
FT Cycle-1 0.6 0.56 (0.08) 94 
(-20  ̊C) 18 17.55 (0.78) 97 
FT Cycle-2 0.6 0.57 (0.12) 95 
(-20  ̊C) 18 17.42 (2.67) 96 
FT Cycle-3 0.6 0.54 (0.06) 89 
(-20  ̊C) 18 15.94 (2.02) 88 
 Stability (%) = mean measured level at the indicated time divided by mean measured level at base line X 100 (n=5). RT, room temperature (22  ̊C). 
FT, Freeze-thaw cycle; samples were frozen at-20  ̊C and thaw at RT. 
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Application to volunteer samples  
Fig. 5 depicts an overlay chromatogram of samples collected from a 
healthy volunteer before and 6.0 h after the ingestion of a single 
dose of 10 mg amlodipine. Measured levels of amlodipine were zero 
and 5.6 ng/ml, respectively. 
 
 
Fig. 5: MRM chromatograms of plasma samples obtained from a 




The described LC-MS/MS method is simple, precise, and accurate for 
rapid measurement of amlodipine level using 0.5 ml human plasma. 
The assay was used to study amlodipine stability under various 
condition encountered in the clinical laboratory. Further, the assay 
was successfully applied to determine amlodipine level in human 
plasma samples obtained from a healthy volunteer.  
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